American Capital Management Has Lowered Its Gilead Sciences (GILD) Position; Bristol Myers Squibb Co (BMY) Sentiment Is 0.94

April 22, 2018 - By Darrin Black

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Bristol Myers Squibb Co (BMY) investors sentiment decreased to 0.94 in 2017 Q4. It’s down -0.09, from 1.03 in 2017Q3. The ratio has worsened, as 563 institutional investors increased and opened new positions, while 598 decreased and sold their holdings in Bristol Myers Squibb Co. The institutional investors in our database now have: 1.11 billion shares, up from 1.11 billion shares in 2017Q3. Also, the number of institutional investors holding Bristol Myers Squibb Co in top ten positions decreased from 45 to 36 for a decrease of 9. Sold All: 72 Reduced: 526 Increased: 457 New Position: 106.

American Capital Management Inc decreased Gilead Sciences (GILD) stake by 12.93% reported in 2017Q4 SEC filing. American Capital Management Inc sold 5,115 shares as Gilead Sciences (GILD)’s stock rose 1.93%. The American Capital Management Inc holds 34,431 shares with $2.47M value, down from 39,546 last quarter. Gilead Sciences now has $96.09B valuation. The stock decreased 0.99% or $0.74 during the last trading session, reaching $73.7. About 4.23 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 22, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 earnings per share, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07B for 11.59 P/E if the $1.59 EPS becomes a reality. After $1.60 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

American Capital Management Inc increased Aerovironment (NASDAQ:AVAV) stake by 127,619 shares to 1.44M valued at $80.97 million in 2017Q4. It also upped Charles River Labs (NYSE:CRL) stake by 28,050 shares and now owns 175,950 shares. Commvault Systems (NASDAQ:CVLT) was raised too.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, February 7 by BMO Capital Markets. As per Monday, October 16, the company rating was maintained by Robert W. Baird. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Maxim Group on Friday, April 29. The firm earned “Hold” rating on Wednesday, September 9 by Jefferies. The rating was maintained by Leerink Swann on Thursday, October 19 with “Market Perform”. The rating was maintained by Cowen & Co on Tuesday, July 25 with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25. The firm has “Hold” rating by Maxim Group given on Tuesday, May 30. The firm earned “Neutral” rating on Wednesday, December 20 by Credit Suisse. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Neutral” rating given on Monday, January 18 by Bank of America.

Since January 2, 2018, it had 0 buys, and 18 sales for $39.95 million activity. $4.68 million worth of stock was sold by WILSON GAYLE E on Friday, February 9. Another trade for 5,833 shares valued at $467,138 was sold by Cogan John Francis. $1.97M worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Alton Gregg H. On Wednesday, February 21 the insider Washington Robin L sold $401,566. $4.18 million worth of stock was sold by MARTIN JOHN C on Thursday, February 1. Shares for $8.02 million were sold by Meyers James R.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It fall, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Usca Ria Limited Liability owns 91,817 shares for 0.73% of their portfolio. North Point Portfolio Managers Oh holds 2.23% in Gilead Sciences, Inc. (NASDAQ:GILD) or 184,157 shares. Mutual Of Omaha Commercial Bank Wealth Management holds 6,268 shares. Needham Management Limited Liability Com, a New York-based fund reported 161,000 shares. Riverhead Management Ltd Liability Com holds 97,584 shares or 0.3% of its portfolio. Bar Harbor holds 0.19% in Gilead Sciences, Inc. (NASDAQ:GILD) or 5,014 shares. Bailard Incorporated stated it has 0.17% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Wagner Bowman Management Corporation invested in 0.06% or 3,211 shares. Natixis Asset Mgmt owns 77,730 shares or 0.62% of their US portfolio. Rhenman And Prtnrs Asset has invested 2.77% in Gilead Sciences, Inc. (NASDAQ:GILD). Hamilton Point Invest Advsrs Limited Liability Corporation reported 0.83% in Gilead Sciences, Inc. (NASDAQ:GILD). Paradigm Asset Mngmt Llc owns 43,410 shares. 4,411 were accumulated by First Personal Services. Cornerstone Advsr Inc accumulated 0.36% or 44,000 shares. Narwhal Mgmt invested in 0.7% or 42,310 shares.

Since January 1, 0001, it had 1 buying transaction, and 1 insider sale for $85,985 activity.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $83.66 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 83.89 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on April, 26 before the open. They expect $0.84 earnings per share, 0.00% or $0.00 from last year’s $0.84 per share. BMY’s profit will be $1.37B for 15.23 P/E if the $0.84 EPS becomes a reality. After $0.68 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

Ratings analysis reveals 33% of Bristol-Myers Squibb Co’s analysts are positive. Out of 3 Wall Street analysts rating Bristol-Myers Squibb Co, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $52.0 while the high is $70. The stock’s average target of $62.33 is 21.81% above today’s ($51.17) share price. BMY was included in 4 notes of analysts from November 18, 2015. Barclays Capital maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, September 9 with “Equal Weight” rating. The firm earned “Buy” rating on Monday, December 19 by Jefferies. The firm earned “Hold” rating on Friday, October 28 by Deutsche Bank.

The stock decreased 0.85% or $0.44 during the last trading session, reaching $51.17. About 11.67M shares traded or 31.31% up from the average. Bristol-Myers Squibb Company (BMY) has risen 11.37% since April 22, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Terril Brothers Inc. holds 9.54% of its portfolio in Bristol-Myers Squibb Company for 505,594 shares. Healthinvest Partners Ab owns 43,400 shares or 5.61% of their US portfolio. Moreover, Sabby Management Llc has 5.29% invested in the company for 931,807 shares. The New Jersey-based Blackhill Capital Inc has invested 5.16% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 90,000 shares.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>